PT-141 10 Hubio Pharm USA

PT-141 (Bremelanotide) 10 mg Lyophilized Peptide Vial, Hubio Pharm

Full description

PT-141 is the research code for bremelanotide, a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, with its main activity at the MC4 receptor. Unlike the PDE5 inhibitors, it works through the central nervous system rather than through direct action on penile blood flow, which is why it is studied as a separate pharmacological route.

The peptide is supplied as a lyophilized (freeze-dried) powder in a single 10 mg vial. The dry format keeps the peptide stable through storage and transport and allows it to be dissolved in the solvent the specific laboratory protocol requires.

Bremelanotide itself is an approved prescription medicine in the United States, where it is marketed for hypoactive sexual desire disorder in premenopausal women. The 10 mg lyophilized vial offered here is not that approved pharmaceutical form: it is a research-grade presentation, and it is supplied strictly for laboratory work.

Each vial carries the manufacturer's original security sticker with a verification code, so authenticity can be checked against the Hubio Pharm database before use. Batch documentation, including the certificate of analysis, is available on request.

Specifications

Storage and handling

Keep the vial sealed and dry until use. Store at -20 °C for long-term storage. Protect from light and moisture and avoid repeated temperature cycling. If reconstituted for a laboratory protocol, follow that protocol's solvent, concentration and stability requirements and keep the solution refrigerated. Keep out of the reach of children.

Important information

This product is a research chemical supplied for laboratory research use only. The 10 mg vial is not an approved pharmaceutical form and is not intended for diagnosis, treatment, cure or prevention of any disease. No human safety or efficacy data is provided or implied for this presentation. Not for injection, ingestion or any form of human consumption. No dosing or administration information is supplied.

For reference, bremelanotide as an approved medicine carries documented cardiovascular effects, including transient increases in blood pressure, and is contraindicated in people with uncontrolled hypertension. It is not to be used without medical supervision. Handle with standard laboratory precautions and dispose of according to local regulations. By purchasing, the buyer confirms they are a qualified researcher or institution and will use the product accordingly.